On the ropes, Opexa shares blast­ed by PhI­Ib mul­ti­ple scle­ro­sis tri­al flop

9 years ago
R&D

In­dus­try vet Ken Moch jumps to the helm of a small biotech with big dreams for treat­ing Alzheimer’s

9 years ago
R&D

That En­gMab buy­out? Cel­gene agreed to pay up to $3B for BC­MA-tar­get­ing drug

9 years ago
Deals

FDA flash­es red light on Sanofi man­u­fac­tur­ing in­frac­tion, threat­en­ing a loom­ing block­buster de­ci­sion

9 years ago
Pharma

AS­CO star, backed by bil­lion­aires, goes to Astel­las in $1.4 bil­lion buy­out

9 years ago
Deals

Bil­lion­aire Be­zos, Arch car­ry a torch for ag­ing R&D, back $116M mega-round for Uni­ty

9 years ago
R&D

FDA slaps a par­tial hold on one of As­traZeneca's cru­cial dur­val­um­ab pro­grams

9 years ago
R&D

GSK dumps a late-stage HIV drug; MIT of­fers sup­port for tech start-ups; Ra Phar­ma clos­es flat af­ter $92M IPO

9 years ago
News Briefing

Pro­QR shares spike on pos­i­tive PoC study for lead CF drug

9 years ago
R&D

Bruised by a pun­ish­ing Op­di­vo fail­ure, Bris­tol-My­ers looks to shake up the busi­ness, ac­cel­er­ate R&D

9 years ago
R&D

Al­ler­gan’s ex­ec­u­tive team or­ches­trates a $200M buy­out to beef up gas­troen­terol­o­gy pipeline

9 years ago
Deals

Turn­ing phar­ma castoffs in­to an in­stant for­tune, Vivek Ra­maswamy’s My­ovant bags a $218M IPO

9 years ago
Financing

Hu­mana spells out its con­di­tion­al Ex­ondys 51 cov­er­age pol­i­cy — strings at­tached

9 years ago
Pharma

Au­ven Ther­a­peu­tics sells PhI­II dry eye dis­ease drug to Sun for $40M-plus

9 years ago
Pharma

GV backs new ge­nomics R&D up­start; Ver­tex ad­vances plans for next-gen CF drugs

9 years ago
News Briefing

Glax­o­SmithK­line sounds taps for a once-mighty R&D pro­gram

9 years ago
R&D

Boehringer flags PhI­II suc­cess for an­oth­er Hu­mi­ra knock­off, set­ting up a crowd­ed field of cheap­er ri­vals — ...

9 years ago
R&D

Bio­gen qui­et­ly whisks away its $544M au­toim­mune ri­val to Cel­gene

9 years ago
R&D

Mer­ck and No­var­tis chiefs out­line what's on the M&A menu in 2017

9 years ago
R&D

As­traZeneca cel­e­brates a PhI­II PARP suc­cess for Lyn­parza, putting pres­sure on Tesaro ri­val

9 years ago
R&D

The clock is tick­ing on Eli Lil­ly’s big Alzheimer’s gam­ble; Pluris­tem reach­es terms on $30M in­vest­ment from Chi­na ...

9 years ago
News Briefing

Por­to­la caps a prob­lem-plagued year with an ap­pli­ca­tion for an­ti­co­ag­u­lant be­trix­a­ban

9 years ago
R&D

Dipex­i­um shares evis­cer­at­ed af­ter lead an­tibi­ot­ic flops on a full slate of PhI­II end­points

9 years ago
R&D

No­var­tis promis­es a speedy CAR-T pitch, boasts about its slate of block­busters-to-be

9 years ago
R&D
Pharma
First page Previous page 1156115711581159116011611162 Next page Last page
A service from the Financial Times